NASDAQ:ANIX March 2026 Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences' current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify ...

Core Insights - Anixa Biosciences has received a patent for its breast cancer vaccine technology in China, extending intellectual property protection until 2040, which enhances its global patent portfolio and supports future commercialization strategies [1][3]. Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes a breast cancer vaccine developed in collaboration with Cleveland Clinic [5]. Vaccine Technology - The breast cancer vaccine targets human-lactalbumin, a protein linked to lactation that is abnormally expressed in certain breast cancers, aiming to prime the immune system to prevent tumor formation without damaging normal tissue [2][4]. Clinical Development - A Phase 1 clinical trial for the breast cancer vaccine has been completed, with full results to be presented at the San Antonio Breast Cancer Symposium on December 11, 2025 [4]. Intellectual Property Strategy - The newly issued patent reinforces Anixa's intellectual property strategy, allowing for broader international development and commercialization opportunities in regions with high breast cancer incidence [3][4].

Core Insights - Anixa Biosciences has received a Notice of Allowance for a new patent related to its breast cancer vaccine technology from the Chinese National Intellectual Property Administration, expanding its global intellectual property coverage [1][2] - The patent will provide composition of matter protection for the breast cancer vaccine in China, extending IP protection into at least the 2040s [1] - The breast cancer vaccine targets human α-lactalbumin, a protein aberrantly expressed in certain breast cancers, aiming to prime the immune system for tumor prevention [4] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [6] - The company’s vaccine platform targets high-incidence cancers and aims to transform cancer prevention strategies [5] - Anixa's business model involves partnerships with renowned research institutions to develop and commercialize innovative cancer therapies [6] Market Context - Breast cancer is the most commonly diagnosed cancer among women in China, with a rising incidence over the past two decades, highlighting the need for innovative preventative solutions like Anixa's vaccine [3] - The new patent complements existing patents in the United States and other jurisdictions, reinforcing Anixa's leadership in cancer immunotherapy [2] - The allowance of the patent strengthens Anixa's ability to pursue strategic global opportunities in regions with high breast cancer burdens [3]

Core Insights - Anixa Biosciences has made significant progress in its clinical and pre-clinical development programs in 2025, maintaining fiscal discipline while advancing its oncology treatment initiatives [1][5] Financial Performance - The company has maintained an average annual cash burn of approximately $5–6 million, which is significantly lower than typical for development-stage biotechnology companies [2] - In the most recent fiscal year, the cash burn was limited to $7 million while advancing two clinical trials [2] - Anixa ended the most recent quarter with over $17 million in cash and no debt, providing more than two years of operational runway [3] Capital Structure - Anixa has a clean capital structure with approximately 32 million common shares outstanding and no warrants [4] - Directors and senior management have consistently purchased stock on the open market, collectively investing millions of dollars, indicating strong belief in the company's long-term value [4] Clinical Programs - The CAR-T therapy program targeting recurrent, platinum-resistant ovarian cancer is progressing, with three dose-escalation cohorts completed in the Phase 1 trial [6][7] - Encouraging signs of efficacy have been observed, with one patient surviving two years post-treatment, significantly exceeding the typical four-month median survival for this population [7] - The breast cancer vaccine, developed in collaboration with Cleveland Clinic, is nearing enrollment completion in its Phase 1 trial, with over 70% of patients showing protocol-defined immune responses [9][11] Future Milestones - Key milestones for the second half of 2025 include final Phase 1 data for the breast cancer vaccine, anticipated FDA interactions, and the initiation of the fourth cohort for the CAR-T ovarian cancer program [15][17] - The company is preparing to extend its vaccine platform to target prostate, lung, and colon cancers, addressing substantial unmet needs in these areas [13][14]